כל המחקרים
גיוסשלב 3התערבותי

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Researchers are looking for adults, aged 18 to 99, to take part in a study testing a new medicine called Maridebart Cafraglutide. This medicine is for people who have obstructive sleep apnea (OSA), which means their breathing repeatedly stops and starts during sleep. You also need to be using a positive airway pressure (PAP) machine, like a CPAP, and be overweight or have obesity. The study wants to find out if this new medicine can help improve your sleep apnea symptoms and if it's safe to use over about a year (52 weeks). Half the people in the study will get the new medicine, and the other half will get a placebo (a dummy medicine with no active ingredients).

במבט חטוף

סטטוס
גיוס
שלב
שלב 3
נותן חסות
Amgen
יעד הרשמה
250
התחל
19 דצמבר 2025
השלמה משוערת
13 Sep 2028

על מה המחקר הזה?

This research study is about a new medicine called Maridebart Cafraglutide. It's being tested in adults who have a common sleep disorder called obstructive sleep apnea, often shortened to OSA. People with OSA find their breathing stops and starts repeatedly while they sleep because their airway becomes blocked. This can lead to poor sleep, tiredness during the day, and other health problems.

Many people with OSA already use a special machine, like a CPAP, to help them breathe better at night. This study is for those who use these machines and are also overweight or have obesity. The main goal is to see if adding this new medicine to their existing treatment can help improve their sleep apnea even more, and if it's safe to use over a long period, specifically 52 weeks (about a year).

If successful, this new medicine could offer another way to help people manage their obstructive sleep apnea, especially for those who are also dealing with overweight or obesity. It's an important step in finding more ways to help people get better rest and improve their overall health.

נקודות עיקריות

  • This study is testing a new medicine for sleep apnea in adults.
  • Participants must use a PAP machine and be overweight or have obesity.
  • The study lasts about one year and involves regular clinic visits.
  • You might get the new medicine or a dummy medicine (placebo).
  • You'll have sleep tests, which may involve temporarily pausing PAP use.
  • It's important to discuss any concerns with the study team.

מי עשוי להיות זכאי?

To join this study, you need to be an adult between 18 and 99 years old. You must have been diagnosed with obstructive sleep apnea (OSA) and your sleep test results should show a certain number of breathing pauses or shallow breaths per hour. You also need to be overweight or have obesity, based on your Body Mass Index (BMI).

Crucially, you must already be using a PAP machine (like a CPAP) for your sleep apnea and have been using it regularly for at least three months. You should also plan to continue using it throughout the study. Interestingly, you also need to have tried to lose weight through diet and exercise at least once before, even if it wasn't successful.

There are also some reasons why you might not be able to join. For example, if you've had surgery for your sleep apnea, have certain breathing problems like central sleep apnea, or other serious health conditions, you might not be suitable. Also, if you use other devices for your sleep apnea besides a PAP machine, you might need to stop using them to join the study.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Are you between 18 and 99 years old?
  2. Have you been diagnosed with obstructive sleep apnea (OSA) and use a PAP machine?
  3. Have you been using a PAP machine consistently for at least 3 months?
  4. Are you overweight or have obesity (a BMI of 27 or more)?
  5. Have you tried to lose weight through diet and exercise before?
  6. Have you NOT had any surgery for sleep apnea or serious breathing problems like central sleep apnea?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If you decide to take part, you'll be in the study for about 52 weeks, which is roughly one year. You'll be randomly assigned to either receive the new medicine, Maridebart Cafraglutide, or a placebo (a dummy medicine with no active ingredients). This decision is made by chance, like flipping a coin, and neither you nor the study team will know which you are receiving, to ensure fair results.

Throughout the study, you'll have regular visits to the clinic for health checks, to discuss any side effects, and to get your study medicine. You'll continue to use your PAP machine as usual. You'll also have some sleep tests (like polysomnography) at different times to see how your sleep apnea is changing. There will be a period during some of these tests where you might be asked to temporarily stop using your PAP machine for up to 7 days, to allow researchers to specifically measure the medicine's effect. The team will explain exactly what's involved at each step and how long each visit might take.

סיכונים ותועלות פוטנציאליים

Participating in this study might offer potential benefits, such as potentially improving your sleep apnea symptoms with the new medicine. You'll also receive careful medical attention and monitoring throughout the study. However, there are potential risks, like experiencing side effects from the study medicine, which are not yet fully known. There's also no guarantee that the medicine will work for you. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

מיקומים (56)

  • Valley Clinical Trials
    מיקוד מאומת
    Northridge, United States· גיוס
  • Peninsula Research Associates
    מיקוד מאומת
    Rolling Hills Estates, United States· גיוס
  • Teradan Clinical Trials
    מיקוד מאומת
    Brandon, United States· גיוס
  • מרכז מחקר הגורל
    מיקוד מאומת
    פאלמטו ביי, ארצות הברית· גיוס
  • Clinical Research Center Of Florida
    מיקוד מאומת
    Pompano Beach, United States· גיוס
  • NeuroTrials Research
    מיקוד מאומת
    אטלנטה, ארצות הברית· גיוס
  • Basil Clinical
    מיקוד מאומת
    Laurelton, United States· גיוס
  • מחקר ביו-רפואי מונרו
    מיקוד מאומת
    מונרו, ארצות הברית· גיוס
  • CTI Clinical Research Center
    מיקוד מאומת
    סינסינטי, ארצות הברית· גיוס
  • FutureSearch Trials of Neurology
    מיקוד מאומת
    Austin, United States· גיוס
  • Epic Medical Research - DeSoto
    מיקוד מאומת
    DeSoto, United States· גיוס
  • Sleep Therapy & Research Center
    מיקוד מאומת
    סן אנטוניו, ארצות הברית· גיוס

שאלות נפוצות

What is Maridebart Cafraglutide?

It's a new medicine being tested in this study to see if it can help people with obstructive sleep apnea who also use a PAP machine and are overweight or have obesity.

מהו 'פלצבו'?

A placebo is a dummy medicine that looks like the real medicine but contains no active ingredients. It's used to compare against the real medicine to see if it's truly effective.

Do I have to stop using my CPAP machine?

You'll continue using your CPAP machine normally, but for some specific sleep tests during the study, you might be asked to stop using it for up to 7 days.

כמה זמן יימשך המחקר?

The study will last for about 52 weeks, which is roughly one year.

האם אני יכול לעזוב את המחקר בכל עת?

Yes, you have the right to stop participating in the study at any point, for any reason. Your medical care won't be affected if you choose to withdraw.

כיצד לגלות עוד

Amgen Call Center

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "Maridebart Cafraglutide Versus Placebo in Adult Participants…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.